BioLineRx Ltd. is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide), with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, which is being developed and commercialized by Ayrmid Ltd. (globally, excluding Asia) and Gloria Biosciences (in Asia).
BioLineRx is utilizing its end-to-end expertise in development, regulatory affairs, and CMC to advance its innovative pipeline and ensure life-changing discoveries move beyond the bench to the bedside.
Corporate Presentation
PRESENTATION
